Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | MIF | P14174 | 2/20 | 0.34 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.32 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3837050 | 0.77 | GPR3 (0.37) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL29648866 | 0.77 | GPR3 (0.37) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL4701299 | 0.77 | RET (0.42) | HTR2A | |
| SCHEMBL70001 | 0.72 | GPR3 (0.44) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL31296479 | 0.70 | HTR2A (0.48) | GPR3HTR2AMIFALDH1A1TRPA1 | |
| SCHEMBL6550865 | 0.69 | GPR3 (0.41) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL8458737 | 0.69 | GPR3 (0.41) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL13185884 | 0.69 | GPR3 (0.41) | GPR3HTR2AHDAC3HDAC4HDAC7 | |
| SCHEMBL28342704 | 0.67 | IDO1 (0.42) | ALDH1A1 | |
| SCHEMBL4994372 | 0.67 | HTR2A (0.56) | GPR3HTR2AHDAC3HDAC4HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2358737-B1 | RGD-CONTAINING PEPTIDOMIMETICS AND USES THEREOF | STEBA BIOTECH S A (LU) | 2017-03-01 | — | — | EP | claimed |
| CN-102264756-B | RGD-containing peptidomimetics and uses thereof | STEBA BIOTECH N V | 2014-08-06 | — | — | CN | claimed |
| CN-102264756-A | Rgd-containing peptidomimetics and uses thereof | — | 2011-11-30 | — | — | CN | claimed |
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | CARL ZEISS AG (DE) | 2010-08-26 | — | — | US | disclosed |
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | CARL ZEISS AG (DE) | 2010-08-26 | — | — | US | disclosed |
| EP-1330451-B1 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2008-01-23 | — | — | EP | disclosed |
| US-6653478-B2 | Psychological disorders; hypotensive agents | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-11-25 | — | — | US | disclosed |
| EP-1330451-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-07-30 | — | — | EP | disclosed |
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-17 | — | — | US | disclosed |
| EP-1227898-A1 | TRANSIENTLY DYNAMIC FLOW CYTOMETER ANALYSIS SYSTEM | Cytomation, Inc. (US) | 2002-08-07 | — | — | EP | disclosed |
| WO-2002055514-A2 | SUBSTITUTED BENZIMIDAZOL-2-ONES AS VASOPRESSIN RECEPTOR ANTAGONISTS AND NEUROPEPTIDE Y MODULATORS | ORTHO MCNEIL PHARM INC (US) | 2002-07-18 | — | — | WO | disclosed |
| WO-2001028700-A1 | TRANSIENTLY DYNAMIC FLOW CYTOMETER ANALYSIS SYSTEM | CYTOMATION, INC. (US) | 2001-04-26 | — | — | WO | disclosed |
| CN-1069490-A | Urea derivatives | YAMANOUCHI PHARMA CO LTD (JP) | 1993-03-03 | — | — | CN | disclosed |
| US-4824908-A | ENDCAPPED OR COUPLED WITH ISOCYANATE OR ISOTHIOCYANATE COMPOUNDS; BLENDS, VULCANIZED; TIRES, HOSES | JAPAN SYNTHETIC RUBBER CO., LTD. (JP) | 1989-04-25 | — | — | US | disclosed |
| US-4211867-A | ANTISECRETORY AGENTS, HYPOGLYCEMIC AGENTS, ANTIARRHYTHMIA AGENTS | MCNEIL LABORATORIES, INCORPORATED (US) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073842-A1 | Novel substituted benzimidazol-2-ones as vasopressin receptor antagonists and neuropeptide Y modulators | AVPR2, NPY1R, AVPR1B | GPR3 214/4885HTR2A 255/4885MIF 1570/4885 |
| US-20100212548-A1 | Immersion Liquid And Method For Preparing An Organic Compound For An Immersion Liquid | F12, NR1H3, FLI1 | GPR3 2263/4885HTR2A 2691/4885MIF 643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.